{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:18:44Z","timestamp":1794745124617,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["138153"],"award-info":[{"award-number":["138153"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119933","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:50:13Z","timestamp":1789588213000},"page":"119933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and characterization of a doxorubicin-resistant triple-negative breast cancer spheroid model for drug screening purposes"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-0813","authenticated-orcid":false,"given":"Viwe","family":"Fokazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3831-7719","authenticated-orcid":false,"given":"Beynon","family":"Abrahams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamello","family":"Sekhoacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alandi","family":"van Niekerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-8214","authenticated-orcid":false,"given":"Chrisna","family":"Gouws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119933_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a cancer journal clinicians"},{"key":"10.1016\/j.biopha.2026.119933_bib2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ajpath.2013.05.033","article-title":"Triple-negative breast cancer and the need for new therapeutic targets","volume":"183","author":"Engebraaten","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2026.119933_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119933_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119933_bib5","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","author":"Collignon","year":"2016","journal-title":"Breast Cancer Targets Therapy"},{"key":"10.1016\/j.biopha.2026.119933_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2741\/s527","article-title":"The persisting puzzle of racial disparity in triple negative breast cancer: looking through a new lens","volume":"11","author":"Garlapati","year":"2019","journal-title":"Front. Biosci. -Sch."},{"key":"10.1016\/j.biopha.2026.119933_bib7","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18888.1","article-title":"Triple-negative breast cancer: recent treatment advances","volume":"8","author":"Bergin","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.biopha.2026.119933_bib8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: Current and future perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2026.119933_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","article-title":"Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?","volume":"497","author":"Bai","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119933_bib10","unstructured":"Johnson-Arbor, K. & Dubey, R. 2017. Doxorubicin."},{"key":"10.1016\/j.biopha.2026.119933_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/BCTT.S170239","article-title":"Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer","author":"Franco","year":"2018","journal-title":"Breast Cancer Targets Therapy"},{"key":"10.1016\/j.biopha.2026.119933_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3953-6","article-title":"Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins","volume":"18","author":"Lovitt","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119933_bib13","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20204092","article-title":"Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers","volume":"41","author":"Abd El-Aziz","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2026.119933_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-015-0221-1","article-title":"Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp","volume":"15","author":"Alfarouk","year":"2015","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119933_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biotechadv.2013.06.004","article-title":"Different strategies to overcome multidrug resistance in cancer","volume":"31","author":"Saraswathy","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biopha.2026.119933_bib16","first-page":"910","article-title":"2D and 3D cell cultures\u2013a comparison of different types of cancer cell cultures","volume":"14","author":"Kapa\u0142czy\u0144ska","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.biopha.2026.119933_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12079-011-0132-4","article-title":"3D tumour models: novel in vitro approaches to cancer studies","volume":"5","author":"Nyga","year":"2011","journal-title":"J. Cell. Commun. Signal."},{"key":"10.1016\/j.biopha.2026.119933_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/adt.2015.670","article-title":"Drug discovery approaches utilizing three-dimensional cell culture","volume":"14","author":"Ryan","year":"2016","journal-title":"Assay. Drug. Dev. Technol."},{"issue":"23","key":"10.1016\/j.biopha.2026.119933_bib19","doi-asserted-by":"crossref","first-page":"12827","DOI":"10.3390\/ijms222312827","article-title":"The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis","volume":"22","author":"Ghasemi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119933_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2014.00040","article-title":"vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies","volume":"4","author":"Mcdermott","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119933_bib21","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/cells12151980","article-title":"A novel NCI-H69AR drug-resistant small-cell lung cancer mini-tumor model for anti-cancer treatment screening","volume":"12","author":"Van Niekerk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119933_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/molecules26030605","article-title":"Anticancer potential of Sutherlandia frutescens and Xysmalobium undulatum in LS180 colorectal cancer mini-tumors","volume":"26","author":"Gouws","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119933_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/toxsci\/kfs122","article-title":"Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line","volume":"127","author":"Fey","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2026.119933_bib24","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1073\/pnas.1721508115","article-title":"Molecular mechanism of ATP versus GTP selectivity of adenylate kinase","volume":"115","author":"Rogne","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119933_bib25","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1007\/s00262-023-03470-y","article-title":"Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer","volume":"72","author":"Egelston","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119933_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119933_bib27","series-title":"Muscle and exercise physiology","article-title":"Human body composition and muscle mass","author":"Duda","year":"2019"},{"key":"10.1016\/j.biopha.2026.119933_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejps.2012.03.012","article-title":"Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin","volume":"46","author":"Jovelet","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119933_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10937404.2024.2407452","article-title":"vitro models to evaluate multidrug resistance in cancer cells: Biochemical and morphological techniques and pharmacological strategies","volume":"28","author":"Madrid","year":"2025","journal-title":"J. Toxicol. Environ. Health Part. B"},{"key":"10.1016\/j.biopha.2026.119933_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cyto.1072","article-title":"Detection of MRP functional activity: Calcein AM but not BCECF AM as a multidrug resistance-related protein (MRP1) substrate","volume":"46","author":"Olson","year":"2001","journal-title":"Cytometry"},{"key":"10.1016\/j.biopha.2026.119933_bib31","unstructured":"Riss, T.L., Moravec, R.A., Niles, A.L., Duellman, S., Benink, H.A., et al. 2016. Cell viability assays. Assay guidance manual [Internet]."},{"key":"10.1016\/j.biopha.2026.119933_bib32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/15376516.2018.1485805","article-title":"Toxicity and anti-prolific properties of Xysmalobium undulatum water extract during short-term exposure to two-dimensional and three-dimensional spheroid cell cultures","volume":"28","author":"Calitz","year":"2018","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.biopha.2026.119933_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111863","article-title":"Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide","volume":"13","author":"Cavaco","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119933_bib34","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.2147\/OTT.S249756","article-title":"Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model","volume":"13","author":"Huang","year":"2020","journal-title":"Oncotargets Ther."},{"key":"10.1016\/j.biopha.2026.119933_bib35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2020.08.075","article-title":"Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines","volume":"533","author":"Muguruma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119933_bib36","series-title":"Biomechanics and Functional Tissue Engineering","article-title":"A purpose-built system for culturing cells as in vivo mimetic 3D structures","author":"Wrzesinski","year":"2021"},{"key":"10.1016\/j.biopha.2026.119933_bib37","series-title":"Next Generation Culture Platforms for Reliable In Vitro Models: Methods and Protocols","article-title":"Clinostat 3D Cell Culture: Protocols for the Preparation and Functional Analysis of Highly Reproducible, Large, Uniform Spheroids and Organoids","author":"Wrzesinski","year":"2021"},{"key":"10.1016\/j.biopha.2026.119933_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3253","article-title":"A novel NCI-H69V small cell lung cancer functional mini-tumor model for future treatment screening applications","volume":"38","author":"Van Der Merwe","year":"2022","journal-title":"Biotechnol. Progress."},{"key":"10.1016\/j.biopha.2026.119933_bib39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fonc.2020.00660","article-title":"Adenylate kinase and metabolic signaling in cancer cells","volume":"10","author":"Klepinin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119933_bib40","first-page":"1835","article-title":"Intracellular ATP levels determine cell death fate by apoptosis or necrosis","volume":"57","author":"Eguchi","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119933_bib41","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to Cisplatin-induced DNA damage","volume":"2010","author":"Basu","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119933_bib42","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.3390\/molecules26082382","article-title":"Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies","volume":"26","author":"Mirzaei","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119933_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12935-023-03124-0","article-title":"Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics","volume":"23","author":"Carneiro","year":"2023","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119933_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biology3020345","article-title":"Advanced cell culture techniques for cancer drug discovery","volume":"3","author":"Lovitt","year":"2014","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2026.119933_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jbiotec.2014.11.008","article-title":"A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype","volume":"193","author":"Cassereau","year":"2015","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119933_bib46","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.32604\/or.2025.067126","article-title":"Cancer 3D Models: Essential tools for understanding and overcoming drug resistance","volume":"33","author":"Stojanov","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.biopha.2026.119933_bib47","series-title":"The Tumor Microenvironment: Methods and Protocols","article-title":"Spheroids as a 3D model of the hypoxic tumor microenvironment","author":"Kirsh","year":"2023"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:52:23Z","timestamp":1794743543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S0753332226009698"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119933","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of a doxorubicin-resistant triple-negative breast cancer spheroid model for drug screening purposes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119933"}}